Supplementary Tables S1-S14 from Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence

Supplementary Table S1 details all IM and control samples with associated profiling platforms, including targeted DNA sequencing, WGS, single-cell RNA-seq, bulk RNA-seq, shotgun metagenomics, EM-seq, and Stereo-seq datasets. Supplementary Table S2 summarizes major genomic and molecular findings across different countries and ancestral backgrounds. Supplementary Table S3 lists significantly mutated genes identified in non-hypermutated intestinal metaplasia samples. Supplementary Table S4 shows pathways up-regulated in intestinal lineage cells exhibiting high KRAS/ERK expression. Supplementary Table S5 provides a catalog of established IM and normal gastric organoid lines with relevant metadata. Supplementary Table S6 reports Hallmark and GO pathway enrichment analyses comparing KRAS/MAPK-mutated versus wild-type IM, and severe versus mild IM organoids. Supplementary Table S7 displays country- and risk-group-specific proportions of SBS mutational signatures derived from targeted panel sequencing. Supplementary Table S8 shows correlations between mutational signature exposures and patient age in IM samples, including significance from Pearson’s and Spearman’s tests with and without outliers. Supplementary Table S9 lists germline variants occurring in known somatic driver genes among IM patients. Supplementary Table S10 summarizes univariate and multivariate logistic regression analyses linking clinical and molecular risk factors to dysplasia and early gastric neoplasia. Supplementary Table S11 shows associations between bacterial genera abundance and PIGR mutational status in IM samples. Supplementary Table S12 profiles the composition of the oral microbiome from saliva samples of IM patients. Supplementary Table S13 lists Seahorse mitochondrial stress test instrument parameters and assay conditions. Supplementary Table S14 provides Seahorse mitochondrial stress test settings specific to DCA treatment experiments.